# Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

> **NCT00717925** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Inotuzumab Ozogamicin (CMC-544)

## Key facts

- **NCT ID:** NCT00717925
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717925, "Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00717925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*